Novavax Signs a Clinical Trial Agreement with Nucleus Network to Initiate the Clinical Study Evaluating NVX-CoV2373 Against COVID-19

 Novavax Signs a Clinical Trial Agreement with Nucleus Network to Initiate the Clinical Study Evaluating NVX-CoV2373 Against COVID-19

Shots:

  • Novavax deploys expertise of the Nucleus to commence P-I clinical study assessing NVX-CoV2373 for the first confirmed COVID-19 vaccines study outside the US. The P-I study is expected to be initiated in mid-May with its preliminary immunogenicity and safety results in July
  • The study will be the third confirmed global COVID-19 vaccine trial and the first in Australia (at Melbourne and Brisbane clinical sites). Nucleus will assist Novavax to undertake P-I study and fast track NVX-CoV2373 for its early development
  • Nucleus has applied its highest level of transmission-based precautions within its clinical units including its clinical staff, which makes it an ideal partner for Novavax to rapidly develop a vaccine for COVID-19

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Nucleus

Related News: Novavax Accelerates the Initiation of Clinical Study for NVX-CoV2373 to Mid-May 2020

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post